POS0037 DOES IMAGING OF THE SACROILIAC JOINT DIFFER IN PATIENTS PRESENTING WITH UNDIAGNOSED BACK PAIN AND PSORIASIS, ACUTE ANTERIOR UVEITIS, AND COLITIS: AN INCEPTION COHORT STUDY
Authors: W. P. Maksymowych, U. Weber, J. Chan, R. Carmona, J. Yeung, S. Aydin, J. Reis, L. Martin, A. Masetto, O. Ziouzina, D. Mosher, S. Keeling, S. Rohekar, R. Dadashova, J. Paschke, A. Carapellucci, R. G. Lambert
Journal: Annals of the Rheumatic Diseases (2021)

Background: Axial spondyloarthritis (axSpA) presents diagnostic challenges incurring a delay of up to a decade and relies considerably on radiographic and MRI evidence of sacroiliitis which has led to the development of classification criteria which also rely on imaging. However, it has been suggested that such criteria may not be appropriate for axSpA patients presenting with other forms of SpA, especially psoriatic, because imaging features may vary in frequency and/or may be atypical. This hypothesis has never been tested in a prospective inception cohort of patients presenting with undiagnosed back pain. Objectives: We aimed to compare the spectrum of radiographic and MRI abnormalities in the sacroiliac joint (SIJ) of an inception cohort of patients presenting with undiagnosed back pain and psoriasis, iritis, and colitis. Methods: We used data from the prospective multicenter Screening for Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis (SASPIC) Study, which is aimed at early detection of axial SpA in patients referred by the respective specialist after first presenting with these disorders. Consecutive patients ≤45 years of age with ≥3 months undiagnosed back pain with any one of psoriasis, AAU, or colitis undergo routine clinical evaluation by a rheumatologist for axial SpA followed by imaging. In SASPIC I, MRI evaluation of the SIJ was ordered per rheumatologist decision. In SASPIC II, MRI evaluation was ordered for all patients. Radiographs and MRI scans were assessed by two central readers and comparisons of the three groups were based on concordant assessments of imaging features. Evaluation of MRI scans included both global assessment for presence/absence of axSpA with confidence scale (-10 to +10), active and structural lesions typical of axSpA per recent ASAS definitions, and granular assessment of individual lesions according to SIJ quadrants and halves in consecutive semicoronal slices through the SIJ. Groups were compared by ANOVA and the chi-square test. Results: A total of 240 patients were recruited, 143 from SASPIC I and 97 from SASPIC II, 101 (42.1%) being diagnosed with axSpA (65.3% male, mean age 34.4 years, mean symptom duration 8.7 years, B27 positive 55.4%). Mean age of colitis (N=101), psoriasis (N=61), iritis (N=78) patients were 33.4, 36.6, 34.3 years, respectively, mean symptom duration was 6.8, 7.2, 9.4 years, respectively, and % males were 45.5%, 52.5%, 51.3%, respectively. There were no significant group differences for unilateral versus bilateral radiographic sacroiliitis and no significant differences in the frequencies, type, or distribution of MRI lesions (Table 1). Conclusion: Data from the SASPIC prospective inception cohort does not support the view that imaging of the SIJ differs in psoriatic axSpA, which appears similar to axSpA associated with iritis or colitis. These data support the umbrella concept of axSpA. Imaging Feature Colitis (n=30 ) Psoriasis (n=19 ) Iritis (n=52 ) P value Unilateral sacroiliitis (grade ≥2), N(%) 1 (3.3%) 0 (0%) 2 (3.8%) 0.69 mNY criteria +, N(%) 5 (16.7%) 6 (31.2%) 15 (28.8%) 0.39 Grade of sacroiliitis, mean(SD) 1.8 (2.2) 2.1 (2.7) 2.2 (2.4) 0.76 MRI indicative of axSpA, N(%) 15 (50.0%) 11 (57.9%) 32 (61.5%) 0.60 MRI indicative of axSpA (confidence ≥5/10), N(%) 14 (46.7%) 10 (52.6%) 30 (57.7%) 0.63 MRI active lesion typical of axSpA, N(%) 6 (20.0%) 6 (31.6%) 18 (34.6%) 0.37 MRI structural lesion typical of axSpA, N(%) 11 (36.7%) 7 (36.8%) 18 (34.6%) 0.98 MRI with unilateral lesion (any) 2 (6.7%) 3 (15.8%) 11 (21.2%) 0.22 MRI with unilateral lesion (BME) 1 (3.3%) 2 (10.5%) 5 (9.6%) 0.54 MRI with unilateral lesion (Erosion) 0 (0%) 0 (0%) 3 (5.8%) 0.23 MRI with unilateral lesion (Sclerosis) 1 (3.3%) 1 (5.3%) 3 (5.8%) 0.89 MRI with unilateral lesion (Fat) 0 (0%) 0 (0%) 0 (0%) NA MRI with iliac lesion 17 (56.7%) 12 (63.2%) 32 (61.5%) 0.88 MRI with sacral lesion 12 (40.0%) 11 (57.9%) 31 (59.6%) 0.21 Disclosure of Interests: Walter P Maksymowych Speakers bureau: Abbvie, Janssen, Novartis, Pfizer, UCB, Consultant of: Abbvie, BMS, Boehringer, Galapagos, Gilead, Lilly, Novartis, Pfizer, UCB, Grant/research support from: Abbvie, Novartis, Pfizer, Ulrich Weber: None declared, Jon Chan: None declared, Raj Carmona: None declared, James Yeung: None declared, Sibel Aydin: None declared, Jodie Reis: None declared, Liam Martin: None declared, Ariel Masetto: None declared, Olga Ziouzina: None declared, Dianne Mosher: None declared, Stephanie Keeling: None declared, Sherry Rohekar: None declared, Rana Dadashova: None declared, Joel Paschke: None declared, Amanda Carapellucci: None declared, Robert G Lambert: None declared.